FT Options’s Rocket Pharmaceuticals RCKT Stock Holding History

FT Options’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$36K	Sell	5,000 -32,500	-87%	-$149K	0.05%	137
2017 Q2	$285K	Sell	37,500 -81,941	-69%	-$611K	0.49%	47
2017 Q1	$956K	Buy	119,441 +74,148	+164%	+$499K	1.26%	21
2016 Q4	$1.1M	Buy	45,293 +6,077	+15%	+$173K	1.27%	18
2016 Q3	$1.49M	Buy	39,216 +3,028	+8%	+$95.2K	1.18%	19
2016 Q2	$1.08M	Sell	36,188 -6,200	-15%	-$218K	0.93%	22
2016 Q1	$1.25M	Buy	42,388 +35,783	+542%	+$1.07M	1.31%	17
2015 Q4	$299K	Buy	+6,605	New	+$288K	0.22%	77

Other funds holding RCKT

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SAM

Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

FT Options's RCKT Position: Q3 2017 in Review

FT Options reduced its Rocket Pharmaceuticals (RCKT) stake by 87% in Q3 2017, selling an estimated $149K and leaving 5,000 shares worth $36K. The position accounts for 0.05% of the portfolio, ranked #137.

FT Options first reported a position in RCKT in Q4 2015 and has held it in 8 quarters since. The position peaked at $1.49M in Q3 2016. 34 funds tracked by Wall St. Rank hold RCKT as of Q3 2017.

FT Options held 5,000 shares of Rocket Pharmaceuticals worth $36K as of Q3 2017.
FT Options sold 32,500 Rocket Pharmaceuticals shares in Q3 2017, an estimated $149K.
Rocket Pharmaceuticals made up 0.05% of FT Options's portfolio in Q3 2017, its #137 holding.
FT Options first reported a position in Rocket Pharmaceuticals in Q4 2015 and has held it in 8 quarters since.
FT Options's Rocket Pharmaceuticals position peaked at $1.49M in Q3 2016.
34 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.